经济学视角下我国多适应证药物定价方式探究

阳丰鸿; 简金洋; 刘东旭; 褚淑贞

doi:10.6039/j.issn.1001-0408.2023.17.15

您当前的位置：

首页 >

文章列表页 >

经济学视角下我国多适应证药物定价方式探究

药物经济学 | 更新时间：2023-09-14

- 经济学视角下我国多适应证药物定价方式探究
- Research on pricing methods of multi-indication drugs from the perspective of economics
- 中国药房 2023年34卷第17期页码：2134-2138
- 作者机构：
  
  中国药科大学国际医药商学院，南京　211100
- 作者简介：
  
  硕士研究生。研究方向：医药产业经济及政策、医药技术经济与管理、药品可及性。E-mail：1446385899@qq.con
  教授，硕士生导师，硕士。研究方向：医药产业经济及政策、医药技术经济与管理、药品可及性。电话：025-86185038。 E-mail：1019941160@cpu.edu.cn
- 基金信息：
  
  国家社会科学基金重大项目(15ZDB167)
- DOI：10.6039/j.issn.1001-0408.2023.17.15
  中图分类号： R956
- 纸质出版日期：2023-09-15，
  
  收稿日期：2023-03-29，
  
  修回日期：2023-08-17，
扫描看全文
阳丰鸿,简金洋,刘东旭等.经济学视角下我国多适应证药物定价方式探究 ^Δ[J].中国药房,2023,34(17):2134-2138.

YANG Fenghong,JIAN Jinyang,LIU Dongxu,et al.Research on pricing methods of multi-indication drugs from the perspective of economics[J].ZHONGGUO YAOFANG,2023,34(17):2134-2138.
阳丰鸿,简金洋,刘东旭等.经济学视角下我国多适应证药物定价方式探究 ^Δ[J].中国药房,2023,34(17):2134-2138. DOI： 10.6039/j.issn.1001-0408.2023.17.15.

YANG Fenghong,JIAN Jinyang,LIU Dongxu,et al.Research on pricing methods of multi-indication drugs from the perspective of economics[J].ZHONGGUO YAOFANG,2023,34(17):2134-2138. DOI： 10.6039/j.issn.1001-0408.2023.17.15.

摘要

目的

从经济学角度探讨适合我国的多适应证药物定价方式。

方法

通过梳理多适应证药物近几年在我国医保谈判准入的情况和定价方式，从品牌定价、加权平均标价、风险分担协议下的单一标价3种方式探讨典型国家（瑞典、德国、英国、意大利等）对多适应证药物的价值测算、准入与管理经验，并以社会福利相关理论为支撑，探究单一标价、适应证定价2种多适应证药物定价方式的优劣及使用条件，从而提出适合我国多适应证药物的定价方式。结果与

结论

多适应证药物采用单一标价模式定价在现阶段存在一定的弊端，应适当以协议定价的方式进行补充完善。我国可在借鉴国际经验的基础上，探索合理的药品适应证管理模式，采用以协议定价为主、多种定价方式并存的定价模式，并推进药物经济学评价发展和用药信息收集机制的完善。

Abstract

OBJECTIVE

METHODS

By sorting out the situation and pricing methods of multi-indication drugs in China’s health insurance negotiation in recent years， the experience of typical countries （Sweden， Germany， Britain， Italy， etc.） in the value measurement， access and management of multi-indication drugs were explored with 3 methods， namely， branded pricing， weighted average bidding pricing， and single bidding pricing under the risk sharing agreement. The advantages and disadvantages of the 2 types of multi-indication drug pricing methods， such as single bidding pricing and indication-based pricing， and conditions of use were explored， so as to put forward a pricing method suitable for multi-indication drugs in China.

RESULTS

CONCLUSIONS

The pricing of multi-indication drugs by single bidding pricing mode has certain disadvantages at this stage， and should be supplemented and improved by agreement pricing. Based on international experience， China can explore a reasonable management mode of drug indications， adopt a pricing mode with agreement pricing as the main mode and multiple pricing modes as the coexisting mode， and promote the development of pharmacoeconomic evaluation and the improvement of drug use information collection mechanism.

＆

To explore the pricing methods of multi-indication drugs suitable for China from the economic perspective.

关键词

多适应证药物协议定价价值定价医保准入医保药品支付标准

Keywords

negotiated pricingvalue pricingmedicare insurance accesspayment standards for medicare insurance drug

references

OECD. Addressing challenges in access to oncology medicines[EB/OL].（2020-06-05）[2023-03-05].https：//www.oecd.org/health/health-systems/addressing-challenges- in-access-to-oncology-medicines.htmhttps://www.oecd.org/health/health-systems/addressing-challenges-in-access-to-oncology-medicines.htm.

MESTRE-FERRANDIZ J，DELLAMANO R，PISTOLLATO M，et al. Multi-indication pricing：pros，cons and applicability to the UK[EB/OL].[2023-03-05].https：//ideas.repec.org/p/ohe/sembri/001653.htmlhttps://ideas.repec.org/p/ohe/sembri/001653.html.

PERSSON U，NORLIN J M. Multi-indication and combination pricing and reimbursement of pharmaceuticals：opportunities for improved health care through faster uptake of new innovations[J]. Appl Health Econ Health Policy，2018，16（2）：157-165.

CHANDRA A，GARTHWAITE C. The economics of indication-based drug pricing[J]. N Engl J Med，2017，377（2）：103-106.

NERI M，TOWSE A，GARAU M. Multi-indication pricing（MIP）：practical solutions and steps to move forward[EB/OL].[2023-03-05]. https：//ideas.repec.org/p/ohe/briefg/002084.htmlhttps://ideas.repec.org/p/ohe/briefg/002084.html.

MOSSMANN W，SCHERRER F. PCP1：comparison of the German mixed price model and indication-specific pricing for multi-indication products in oncology[J]. Value Heath，2018，21：S82.

PEARSON S D，DREITLEIN W B，HENSHALL C，et al. Indication-specific pricing of pharmaceuticals in the US healthcare system[J]. J Comp Eff Res，2017，6（5）：397-404.

LAUENROTH V D，STARGARDT T. Pharmaceutical pricing in Germany：how is value determined within the scope of AMNOG?[J]. Value Health，2017，20（7）：927-935.

Department of Health and Social Care. The 2019 voluntary scheme for branded medicines pricing and access[EB/OL].（2018-12-06）[2023-03-05]. https：//assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/761834/voluntary-scheme-for-brandedme- dicines-pricing-and-access-chapters-and-glossary.pdfhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/761834/voluntary-scheme-for-brandedme-dicines-pricing-and-access-chapters-and-glossary.pdf.

JOMMI C，MINGHETTI P. Pharmaceutical pricing policies in Italy[EB/OL]. （2014-11-28）[2023-03-05]. https：//doi.org/10.1007/978-3-319-12169-7_8https://doi.org/10.1007/978-3-319-12169-7_8.

ZOZAYA N，MESTRE J，ALCALÁ B，et al. Medicines with multiple indications：a new multi-year multi-indication pricing model[EB/OL].（2020-06-30）[2023-03-05]. http：//weber.org.es/wp-content/uploads/2020/04/Informe-VOICE-FINAL-Abril-2020-1.pdfhttp://weber.org.es/wp-content/uploads/2020/04/Informe-VOICE-FINAL-Abril-2020-1.pdf.

Department of Health and Social Care. Pharmaceutical price regulation scheme 2014[EB/OL].（2018-12-03）[2023-03-05]. https：//www.gov.uk/government/publications/pharma-ceutical-price-regulation-scheme-2014https://www.gov.uk/government/publications/pharma-ceutical-price-regulation-scheme-2014.

NAVARRIA A，DRAGO V，GOZZO L，et al. Do the current performance-based schemes in Italy really work? “Success fee”：a novel measure for cost-containment of drug expenditure[J]. Value Health，2015，18（1）：131-136.

LEELE B. Patient access schemes：a look behind the scenes[EB/OL].（2015-12-08）[2023-03-05]. https：//pharmaphorum.com/views-and-analysis/patient-accessschemes- a-lookbehind-the-scenes/https://pharmaphorum.com/views-and-analysis/patient-accessschemes-a-lookbehind-the-scenes/.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据